INAB
NASDAQIN8bio Inc.
News · 26 weeks63-60%
2025-12-142026-06-07
Mix3490d
- SEC Filings16(47%)
- Insider10(29%)
- Other8(24%)
Latest news
25 items- PRIN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination TherapiesNEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: "Harnessing γδ T cells through engineering and combination therapies" in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors and hematologic can
- PRIN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years. NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated clinical data from its INB-200 Phase 1 and INB-400 Pha
- SECSEC Form 8-K filed by IN8bio Inc.8-K - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form 424B5 filed by IN8bio Inc.424B5 - IN8BIO, INC. (0001740279) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by IN8bio Inc.SCHEDULE 13D/A - IN8BIO, INC. (0001740279) (Subject)
- INSIDERDirector Fairbairn Emily gifted 724,637 shares (SEC Form 4)4 - IN8BIO, INC. (0001740279) (Issuer)
- SECSEC Form EFFECT filed by IN8bio Inc.EFFECT - IN8BIO, INC. (0001740279) (Filer)
- SECAmendment: SEC Form S-3/A filed by IN8bio Inc.S-3/A - IN8BIO, INC. (0001740279) (Filer)
- PRIN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in GlioblastomaMultidimensional analyses demonstrate that repeated DeltEx DRI dosing preserves immune function, drives tumor microenvironment remodeling, and correlates with improved survival outcomes in glioblastoma Translational data combines advanced artificial intelligence (AI), immunogenomics, histopathology, and spatial transcriptomics to provide mechanistic insights into therapeutic response and disease progression Findings lay the groundwork for rational biomarker discovery, patient stratification, and potential treatment optimization for future DeltEx DRI studies NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-del
- INSIDERSEC Form 4 filed by Director Epperly Corinne4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by CEO Ho William Tai-Wei4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CSO Lamb Lawrence4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by President and COO Rochlin Kate4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairbairn Emily4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF FINANCIAL OFFICER Mccall Patrick4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by Director Greenwood Luba4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by Director Brandt Peter C.4 - IN8BIO, INC. (0001740279) (Issuer)
- INSIDERSEC Form 4 filed by Director Graff Jeremy R.4 - IN8BIO, INC. (0001740279) (Issuer)
- SECSEC Form S-8 POS filed by IN8bio Inc.S-8 POS - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form S-8 POS filed by IN8bio Inc.S-8 POS - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form S-8 POS filed by IN8bio Inc.S-8 POS - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form S-8 POS filed by IN8bio Inc.S-8 POS - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form S-8 POS filed by IN8bio Inc.S-8 POS - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form S-8 filed by IN8bio Inc.S-8 - IN8BIO, INC. (0001740279) (Filer)
- SECSEC Form 10-Q filed by IN8bio Inc.10-Q - IN8BIO, INC. (0001740279) (Filer)
INAB FAQ
7 questionsWhat does IN8bio Inc. do?
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment...Where does INAB stock trade?
IN8bio Inc. (INAB) is listed on NASDAQ.What sector and industry is INAB in?
IN8bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did IN8bio Inc. go public?
IN8bio Inc. (INAB) completed its IPO in 2021.What are analysts saying about INAB?
IN8bio Inc. has had 5 recent analyst actions on file. The most recent action was from Laidlaw: Buy with a $750.00 price target on 2024-03-18. Recent price targets range from $750.00 to $1900.00.What companies are similar to INAB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare INAB side-by-side with any of them on Quantisnow.How can I track INAB on Quantisnow?
Quantisnow aggregates IN8bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INAB to receive live email and push alerts on every new disclosure.